RESUMEN
Pseudopropionibacterium propionicum (P.p.) is an anaerobic, Gram-positive, branching beaded rod that is a component of the human microbiome. An infection of the thoracic cavity with P.p. can mimic tuberculosis (TB), nocardiosis, and malignancy. We present a case of a 77-year-old male who presented with dyspnea and a productive cough who was initially misdiagnosed with TB based on positive acid-fast staining of a pleural biopsy specimen and an elevated adenosine deaminase level of the pleural fluid. He was then diagnosed with nocardiosis based on the Gram stain of his pleural fluid that showed a Gram-positive beaded and branching rod. The pleural fluid specimen was culture-negative, but the diagnosis of thoracic P.p. infection was determined with next-generation sequencing (NGS). The patient was initially treated with imipenem and minocycline, then ceftriaxone and minocycline, and later changed to minocycline only. This report shows the utility of NGS in making a microbiological diagnosis when other techniques either failed to provide a result (culture) or gave misleading information (histopathologic exam, pleural fluid adenosine deaminase determination, and organism morphology on Gram stain).
RESUMEN
BACKGROUND: Lymphocytic colitis (LC) is a chronic disorder characterized by watery diarrhea. This study sought to evaluate if LC recurs after therapy, and the time frame in which this occurs. Secondary objectives included length and type of therapy, drug-free intervals, and reasons for drug discontinuation. METHODS: A retrospective chart review between January 1, 2008 and October 30, 2015 of patients with biopsy-confirmed lymphocytic, collagenous, or microscopic colitis was conducted. Patient-reported average bowel movements/day were reviewed. Demographic data, dates of colonoscopy, follow-up, type and dose of medications used, and therapy start/stop dates were reviewed. RESULTS: Patients presenting with colonoscopic documented LC (n = 114) were predominantly female (88%), Caucasian (97%), with mean bowel movements/day of five. A total of 58/114 (51%) patients were placed on a therapy. Patients taking budesonide saw bowel movements/day reduced from 4.7 to 2.4 compared to 5.8 to 2.8 for those given 5-aminosalicylic acid (5-ASA). First-line medications budesonide and 5-aminosalicylic acid failed in 12/58 (21%) of patients, other drugs also resulted in therapy changes. Thirty-five percent required their initial therapy changed and of those 40% required a second change. Symptom exacerbations were documented during therapy for 19% of patients; therapy changes resulted in good response. CONCLUSIONS: Almost half of all LC cases (56/114) gradually improved without requiring therapy. Seventy-six percent of our treated patients responded well to budesonide when used as the first-line therapy. Similarly, 61.5% responded to 5-ASA. Budesonide was the drug of choice for flares. Tailoring drug therapy to meet individual patient's needs appears to be the best current approach to managing LC.
